Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer.

Piao L, Li H, Teng L, Yung BC, Sugimoto Y, Brueggemeier RW, Lee RJ.

Nanomedicine. 2013 Jan;9(1):122-9. doi: 10.1016/j.nano.2012.03.008.

2.

Investigation of siRNA-loaded polyethylenimine-coated human serum albumin nanoparticle complexes for the treatment of breast cancer.

Abbasi S, Paul A, Prakash S.

Cell Biochem Biophys. 2011 Nov;61(2):277-87. doi: 10.1007/s12013-011-9201-9.

PMID:
21556941
3.

Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity.

Konca YU, Kirshenbaum K, Zuckermann RN.

Int J Nanomedicine. 2014 May 10;9:2271-85. doi: 10.2147/IJN.S57449.

4.

Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells.

Liu L, Li H, Zhang M, Lv X.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):6674-82.

5.

Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.

Xu Y, Ou M, Keough E, Roberts J, Koeplinger K, Lyman M, Fauty S, Carlini E, Stern M, Zhang R, Yeh S, Mahan E, Wang Y, Slaughter D, Gindy M, Raab C, Thompson C, Hochman J.

Mol Pharm. 2014 May 5;11(5):1424-34. doi: 10.1021/mp400584h.

PMID:
24588618
6.

Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.

Sato Y, Note Y, Maeki M, Kaji N, Baba Y, Tokeshi M, Harashima H.

J Control Release. 2016 May 10;229:48-57. doi: 10.1016/j.jconrel.2016.03.019.

PMID:
26995758
7.

Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.

Gindy ME, Feuston B, Glass A, Arrington L, Haas RM, Schariter J, Stirdivant SM.

Mol Pharm. 2014 Nov 3;11(11):4143-53. doi: 10.1021/mp500367k.

PMID:
25317715
8.

Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery.

Wang X, Yu B, Wu Y, Lee RJ, Lee LJ.

Anticancer Res. 2011 May;31(5):1619-26.

PMID:
21617218
9.

Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.

Zhang J, Haas RM, Leone AM.

Anal Chem. 2012 Jul 17;84(14):6088-96. doi: 10.1021/ac3007768.

PMID:
22816783
10.

Synthesis of Polymer-Lipid Nanoparticles by Microfluidic Focusing for siRNA Delivery.

Li Y, Huang X, Lee RJ, Qi Y, Wang K, Hao F, Zhang Y, Lu J, Meng Q, Li S, Xie J, Teng L.

Molecules. 2016 Oct 17;21(10). pii: E1314.

11.

The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery.

Zhang Y, Arrington L, Boardman D, Davis J, Xu Y, DiFelice K, Stirdivant S, Wang W, Budzik B, Bawiec J, Deng J, Beutner G, Seifried D, Stanton M, Gindy M, Leone A.

J Control Release. 2014 Jan 28;174:7-14. doi: 10.1016/j.jconrel.2013.11.006.

PMID:
24240015
12.

Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.

Yang Z, Cai JH, Xie SJ, Li GX, Song WQ, Yan QH, Yan L, Zhang F.

Chin Med J (Engl). 2011 Jun;124(12):1854-61.

13.

Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.

Zhang J, Pei Y, Zhang H, Wang L, Arrington L, Zhang Y, Glass A, Leone AM.

Mol Pharm. 2013 Jan 7;10(1):397-405. doi: 10.1021/mp3005337.

PMID:
23210488
14.

Low-density lipoprotein-mimicking nanoparticles for tumor-targeted theranostic applications.

Lee JY, Kim JH, Bae KH, Oh MH, Kim Y, Kim JS, Park TG, Park K, Lee JH, Nam YS.

Small. 2015 Jan 14;11(2):222-31. doi: 10.1002/smll.201303277.

PMID:
25137631
15.

The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.

Wan X, Zheng X, Pang X, Zhang Z, Jing T, Xu W, Zhang Q.

Int J Pharm. 2015 Apr 30;484(1-2):16-28. doi: 10.1016/j.ijpharm.2015.02.037.

PMID:
25700543
16.

Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery.

Gindy ME, DiFelice K, Kumar V, Prud'homme RK, Celano R, Haas RM, Smith JS, Boardman D.

Langmuir. 2014 Apr 29;30(16):4613-22. doi: 10.1021/la500630h.

PMID:
24684657
17.

Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF.

Okamoto A, Asai T, Kato H, Ando H, Minamino T, Mekada E, Oku N.

Biochem Biophys Res Commun. 2014 Jul 11;449(4):460-5. doi: 10.1016/j.bbrc.2014.05.043.

PMID:
24853808
18.

Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene.

Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB.

Mol Vis. 2007 May 23;13:746-57.

19.

Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells.

Landesman-Milo D, Goldsmith M, Leviatan Ben-Arye S, Witenberg B, Brown E, Leibovitch S, Azriel S, Tabak S, Morad V, Peer D.

Cancer Lett. 2013 Jul 1;334(2):221-7. doi: 10.1016/j.canlet.2012.08.024.

PMID:
22935680
20.

Delivery of kinesin spindle protein targeting siRNA in solid lipid nanoparticles to cellular models of tumor vasculature.

Ying B, Campbell RB.

Biochem Biophys Res Commun. 2014 Apr 4;446(2):441-7. doi: 10.1016/j.bbrc.2014.02.120.

PMID:
24607899
Items per page

Supplemental Content

Support Center